Drugs / DB-1305/BNT325
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05438329 | Jul 2022 → Aug 2027 expected | neoplasm | DualityBio Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-20 | DualityBio Inc. | Results 2026 ESMO Breast Cancer | Presentation of Preliminary Clinical Data for DualityBio and BioNTech’s Next-Generation TROP2 ADC Sacituzumab Drozuntecan in First-Line Advanced TNBC dualitybiologics.com ↗
The data were presented in a Rapid Oral presentation at the 2026 European Society for Medical Oncology Breast Cancer (“ESMO Breast Cancer”) Annual Meeting in Berlin, Germany. |
| 2025-04-29 | DualityBio Inc. | Results DualityBio Presented Early Clinical and Preclinical Data for Novel ADC Therapy Candidates at AACR 2025 dualitybiologics.com ↗
In this cohort, the combination of BNT325/DB-1305 plus BNT327 showed early signs of anti-tumor activity in efficacy evaluable patients (n=13), with 7 patients achieving partial response (PR) and 3 with stable disease (SD). |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DB-1305/BNT325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05438329 ↗ |
| Route | Intravenous | “Administered Injection of Vein (I.V.)” NCT05438329 ↗ |